{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:07:46Z","timestamp":1745467666181,"version":"3.40.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C19677\/A12834","C19677\/A12834"],"award-info":[{"award-number":["C19677\/A12834","C19677\/A12834"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The De-ESCALaTE trial confirmed the superiority of cisplatin over cetuximab in combination with radiotherapy for the treatment of low risk HPV+ oropharyngeal cancer (HPV\u2009+\u2009OPC). However, there were concerns about certain toxicities with the use of cisplatin, in particular nausea, vomiting, dehydration and renal toxicities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The De-ESCALaTE trial collected data on several centre level policies on hydration and anti-emetic use. Univariable and backwards stepwise multivariable logistic regression models were used to model the association between centre level policy variables and severe adverse events (SAEs) of interest and severe (grade 3\u20135) acute toxicities of interest. In addition, the predictive performance of each model was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Centre level policies including the use of a triple anti-emetics regimen pre and post chemotherapy, increased volumes of IV fluids given before and during cisplatin chemotherapy as well as oral fluids advised post chemotherapy, were all associated with a reduced odds of SAEs of interest. Only a policy to give diuretics was associated with a reduction of severe (grade 3\u20135) acute toxicities of interest.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>For centres with HPV\u2009+\u2009OPC patients undergoing chemoradiation, we recommend the use of specific hydration and anti-emetic policies to reduce the rates of relevant SAEs and severe acute toxicities.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s44276-025-00132-7","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:37:20Z","timestamp":1745390240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the effect of differing centre hydration and anti-emetic policies on acute gastrointestinal and renal toxicities in the De-ESCALaTE trial"],"prefix":"10.1038","volume":"3","author":[{"given":"Anthony","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Hazell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulnaz","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5544-6224","authenticated-orcid":false,"given":"Hisham","family":"Mehanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"132_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon JP, le, Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Therapeutic Radiol Oncol. 2009;92:4\u201314.","journal-title":"Radiother Oncol J Eur Soc Therapeutic Radiol Oncol"},{"key":"132_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.radonc.2011.05.036","volume":"100","author":"P Blanchard","year":"2011","unstructured":"Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol J Eur Soc Therapeutic Radiol Oncol. 2011;100:33\u201340.","journal-title":"Radiother Oncol J Eur Soc Therapeutic Radiol Oncol"},{"key":"132_CR3","doi-asserted-by":"crossref","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393:51\u201360.","DOI":"10.1016\/S0140-6736(18)32752-1"},{"key":"132_CR4","doi-asserted-by":"crossref","unstructured":"Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40\u201350.","DOI":"10.1016\/S0140-6736(18)32779-X"},{"key":"132_CR5","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","volume":"36","author":"V Noronha","year":"2018","unstructured":"Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol. 2018;36:1064\u201372.","journal-title":"J Clin Oncol"},{"key":"132_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","volume":"143","author":"JA Hanley","year":"1982","unstructured":"Hanley JA, Barbara JM. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29\u201336.","journal-title":"Radiology"},{"key":"132_CR7","unstructured":"Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer-Verlag; 2009."},{"key":"132_CR8","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.21.01293","volume":"40","author":"N Kiyota","year":"2022","unstructured":"Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II\/III Randomized Controlled Trial. J Clin Oncol. 2022;40:1980\u201390.","journal-title":"J Clin Oncol"},{"key":"132_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1055\/s-0036-1594020","volume":"21","author":"MS Iqbal","year":"2017","unstructured":"Iqbal MS, Chaw C, Kovarik J, Aslam S, Jackson A, Kelly J, et al. Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival. Int Arch Otorhinolaryngol. 2017;21:171\u20137.","journal-title":"Int Arch Otorhinolaryngol"},{"key":"132_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist. 2017;22:609\u201319.","journal-title":"Oncologist"},{"key":"132_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-005-1010-7","volume":"56","author":"H Lajer","year":"2005","unstructured":"Lajer H, Kristensen M, Hansen HH, Nielsen S, Fr\u00f8kiaer J, Ostergaard LF, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharm. 2005;56:535\u201342.","journal-title":"Cancer Chemother Pharm"},{"key":"132_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/0959-8049(94)00420-A","volume":"31A","author":"TR Evans","year":"1995","unstructured":"Evans TR, Harper CL, Beveridge IG, Wastnage R, Mansi JL. A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer. 1995;31A:174\u20138.","journal-title":"Eur J Cancer"},{"key":"132_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.clon.2006.06.011","volume":"18","author":"E Hodgkinson","year":"2006","unstructured":"Hodgkinson E, Neville-Webbe HL, Coleman RE. Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol. 2006;18:710\u20138.","journal-title":"Clin Oncol"},{"key":"132_CR14","first-page":"13","volume":"63","author":"GA Frick","year":"1979","unstructured":"Frick GA, Ballentine R, Driever CW, Kramer WG. Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis. Cancer Treat Rep. 1979;63:13\u20136.","journal-title":"Cancer Treat Rep"},{"key":"132_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/jjco\/hyv203","volume":"46","author":"E Sakaida","year":"2016","unstructured":"Sakaida E, Iwasawa S, Kurimoto R, Ebata T, Imai C, Oku T, et al. Safety of a short hydration method for cisplatin administration in comparison with a conventional method\u2014a retrospective study. Jpn J Clin Oncol. 2016;46:370\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"132_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/jjco\/hyt122","volume":"43","author":"H Horinouchi","year":"2013","unstructured":"Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, et al. Short hydration in chemotherapy containing cisplatin (\u226575 mg\/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol. 2013;43:1105\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"132_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/jjco\/hyt128","volume":"43","author":"K Hotta","year":"2013","unstructured":"Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol. 2013;43:1115\u201323.","journal-title":"Jpn J Clin Oncol"},{"key":"132_CR18","doi-asserted-by":"publisher","first-page":"e074819","DOI":"10.1136\/bmj-2023-074819","volume":"384","author":"GS Collins","year":"2024","unstructured":"Collins GS, Dhiman P, Ma J, Schlussel MM, Archer L, Van Calster B, et al. Evaluation of clinical prediction models (part 1): from development to external validation. BMJ. 2024;384:e074819.","journal-title":"BMJ"},{"key":"132_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/oxfordjournals.aje.a114892","volume":"127","author":"S Piantadosi","year":"1988","unstructured":"Piantadosi S, Byar DP, Green SB. The ecological fallacy. Am J Epidemiol. 1988;127:893\u2013904.","journal-title":"Am J Epidemiol"},{"key":"132_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40537-018-0143-6","volume":"5","author":"G Smith","year":"2018","unstructured":"Smith G. Step away from stepwise. J Big Data. 2018;5:1\u201312.","journal-title":"J Big Data"},{"key":"132_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/toxics3030268","volume":"3","author":"A Callejo","year":"2015","unstructured":"Callejo A, Sed\u00f3-Cabez\u00f3n L, Juan ID, Llorens J. Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies. Toxics. 2015;3:268\u201393.","journal-title":"Toxics"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00132-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00132-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00132-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:37:23Z","timestamp":1745390243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00132-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["132"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00132-7","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AK received fees for consulting, advisory, speaker\u2019s roles and\/or research funding from PUMA BioTechnology, AstraZeneca, Merck, MSD, Bristol-Myers Squibb, Avvinity Therapeutics. HM has personal financial interests with AstraZeneca, MSD, GSK, Sanofi Pasteur, Merck, Warwickshire Head Neck Clinic Ltd; institutional financial interests with AstraZeneca, GSK PLC, Sanofi Pasteur, MSD, GSK Biologicals, Silence Therapeutics; leadership roles: Chief of Liteform Trial Steering Committee, Chair of NIMRAD Trial Steering Committee, President of the British Association of Head Neck Oncologists, Trial Steering Group member of the MRC CTU Cancer Trials Steering Committee, Council member of the International Association of Oral Oncology, Director of the Institute for Head Neck Studies and Education, Secretary of the Head Neck Cancer InterGroup. HM is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care. All other authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained for the De-ESCALaTE trial, the details of which can be found in the previous publication []. Full protocol of the De-ESCALaTE trial can be accessed on .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"25"}}